Taru Tukiainen

Taru Tukiainen

Auto-generated profile, based on publicly available information

Taru Tukiainen

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2016 in Nature
Verified
Journal Article
Open access
PDF file
ECExome Aggregation Consortium
Exome Aggregation Consortium
MLMonkol Lek
Monkol Lek
KKKonrad J. Karczewski
Konrad J. Karczewski
EMEric Vallabh Minikel
Eric Vallabh Minikel
KSKaitlin E. Samocha
Kaitlin E. Samocha
DMDaniel G. MacArthur
Daniel G. MacArthur
Large-scale reference data sets of human genetic variation are critical for the medical and functional interpretation of DNA sequence changes. Here we describe the aggregation and analysis of high-quality exome (protein-coding region) DNA sequence data for 60,706 individuals of diverse ancestries generated as part of the Exome Aggregation Consortium (ExAC). This catalogue of human genetic diversity contains an average of one variant every eight bases of the exome, and provides direct evidence for the presence of widespread mutational recurrence. We have used this catalogue to calculate objective metrics of pathogenicity for sequence variants, and to identify genes subject to strong selection against various classes of mutation; identifying 3,230 genes with near-complete depletion of predicted protein-truncating variants, with 72% of these genes having no currently established human disease phenotype. Finally, we demonstrate that these data can be used for the efficient filtering of candidate disease-causing variants, and for the discovery of human ‘knockout’ variants in protein-coding genes.

12 October 2017 in Nature
Verified
Journal Article
Open access
PDF file
GCGTEx Consortium
GTEx Consortium
TTTaru Tukiainen
Taru Tukiainen
AVAlexandra-Chloé Villani
Alexandra-Chloé Villani
AYAngela Yen
Angela Yen
MRManuel A. Rivas
Manuel A. Rivas
DMDaniel G. MacArthur
Daniel G. MacArthur
X chromosome inactivation (XCI) silences transcription from one of the two X chromosomes in female mammalian cells to balance expression dosage between XX females and XY males. XCI is, however, incomplete in humans: up to one-third of X-chromosomal genes are expressed from both the active and inactive X chromosomes (Xa and Xi, respectively) in female cells, with the degree of ‘escape’ from inactivation varying between genes and individuals1,2. The extent to which XCI is shared between cells and tissues remains poorly characterized3,4, as does the degree to which incomplete XCI manifests as detectable sex differences in gene expression5and phenotypic traits6. Here we describe a systematic survey of XCI, integrating over 5,500 transcriptomes from 449 individuals spanning 29 tissues from GTEx (v6p release) and 940 single-cell transcriptomes, combined with genomic sequence data. We show that XCI at 683 X-chromosomal genes is generally uniform across human tissues, but identify examples of heterogeneity between tissues, individuals and cells. We show that incomplete XCI affects at least 23% of X-chromosomal genes, identify seven genes that escape XCI with support from multiple lines of evidence and demonstrate that escape from XCI results in sex biases in gene expression, establishing incomplete XCI as a mechanism that is likely to introduce phenotypic diversity6,7. Overall, this updated catalogue of XCI across human tissues helps to increase our understanding of the extent and impact of the incompleteness in the maintenance of XCI.

23 March 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
JKJohannes Kettunen
Johannes Kettunen
Ayse DemirkanAyse Demirkan
Ayse Demirkan
PWPeter Würtz
Peter Würtz
HDHarmen H.M. Draisma
Harmen H.M. Draisma
THToomas Haller
Toomas Haller
MAMika Ala-Korpela
Mika Ala-Korpela
Genome-wide association studies have identified numerous loci linked with complex diseases, for which the molecular mechanisms remain largely unclear. Comprehensive molecular profiling of circulating metabolites captures highly heritable traits, which can help to uncover metabolic pathophysiology underlying established disease variants. We conduct an extended genome-wide association study of genetic influences on 123 circulating metabolic traits quantified by nuclear magnetic resonance metabolomics from up to 24,925 individuals and identify eight novel loci for amino acids, pyruvate and fatty acids. The LPA locus link with cardiovascular risk exemplifies how detailed metabolic profiling may inform underlying aetiology via extensive associations with very-low-density lipoprotein and triglyceride metabolism. Genetic fine mapping and Mendelian randomization uncover wide-spread causal effects of lipoprotein(a) on overall lipoprotein metabolism and we assess potential pleiotropic consequences of genetically elevated lipoprotein(a) on diverse morbidities via electronic health-care records. Our findings strengthen the argument for safe LPA-targeted intervention to reduce cardiovascular risk.

22 October 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMarjolein J. Peters
Marjolein J. Peters
RJRoby Joehanes
Roby Joehanes
LPLuke Pilling
Luke Pilling
CSClaudia Schurmann
Claudia Schurmann
KCKaren N. Conneely
Karen N. Conneely
AJAndrew D. Johnson
Andrew D. Johnson
Disease incidences increase with age, but the molecular characteristics of ageing that lead to increased disease susceptibility remain inadequately understood. Here we perform a whole-blood gene expression meta-analysis in 14,983 individuals of European ancestry (including replication) and identify 1,497 genes that are differentially expressed with chronological age. The age-associated genes do not harbor more age-associated CpG-methylation sites than other genes, but are instead enriched for the presence of potentially functional CpG-methylation sites in enhancer and insulator regions that associate with both chronological age and gene expression levels. We further used the gene expression profiles to calculate the ‘transcriptomic age’ of an individual, and show that differences between transcriptomic age and chronological age are associated with biological features linked to ageing, such as blood pressure, cholesterol levels, fasting glucose, and body mass index. The transcriptomic prediction model adds biological relevance and complements existing epigenetic prediction models, and can be used by others to calculate transcriptomic age in external cohorts.

19 April 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BCBeryl B. Cummings
Beryl B. Cummings
JMJamie L. Marshall
Jamie L. Marshall
TTTaru Tukiainen
Taru Tukiainen
MLMonkol Lek
Monkol Lek
SDSandra Donkervoort
Sandra Donkervoort
DMDaniel G. MacArthur
Daniel G. MacArthur
Exome and whole-genome sequencing are becoming increasingly routine approaches in Mendelian disease diagnosis. Despite their success, the current diagnostic rate for genomic analyses across a variety of rare diseases is approximately 25 to 50%. We explore the utility of transcriptome sequencing [RNA sequencing (RNA-seq)] as a complementary diagnostic tool in a cohort of 50 patients with genetically undiagnosed rare muscle disorders. We describe an integrated approach to analyze patient muscle RNA-seq, leveraging an analysis framework focused on the detection of transcript-level changes that are unique to the patient compared to more than 180 control skeletal muscle samples. We demonstrate the power of RNA-seq to validate candidate splice-disrupting mutations and to identify splice-altering variants in both exonic and deep intronic regions, yielding an overall diagnosis rate of 35%. We also report the discovery of a highly recurrent de novo intronic mutation in COL6A1 that results in a dominantly acting splice-gain event, disrupting the critical glycine repeat motif of the triple helical domain. We identify this pathogenic variant in a total of 27 genetically unsolved patients in an external collagen VI–like dystrophy cohort, thus explaining approximately 25% of patients clinically suggestive of having collagen VI dystrophy in whom prior genetic analysis is negative. Overall, this study represents a large systematic application of transcriptome sequencing to rare disease diagnosis and highlights its utility for the detection and interpretation of variants missed by current standard diagnostic approaches.

30 July 2009 in The Analyst
Verified
Journal Article
Closed access
PDF file
PSPasi Soininen
Pasi Soininen
AKAntti J. Kangas
Antti J. Kangas
PWPeter Würtz
Peter Würtz
TTTaru Tukiainen
Taru Tukiainen
TTTuulia Tynkkynen
Tuulia Tynkkynen
MAMika Ala-Korpela
Mika Ala-Korpela
A high-throughput proton (1H) nuclear magnetic resonance (NMR) metabonomics approach is introduced to characterise systemic metabolic phenotypes. The methodology combines two molecular windows that contain the majority of the metabolic information available by 1H NMR from native serum, e.g. serum lipids, lipoprotein subclasses as well as various low-molecular-weight metabolites. The experimentation is robotics-controlled and fully automated with a capacity of about 150–180 samples in 24 h. To the best of our knowledge, the presented set-up is unique in the sense of experimental high-throughput, cost-effectiveness, and automated multi-metabolic data analyses. As an example, we demonstrate that the NMR data as such reveal associations between systemic metabolic phenotypes and the metabolic syndrome (n = 4407). The high-throughput of up to 50 000 serum samples per year is also paving the way for this technology in large-scale clinical and epidemiological studies. In contradiction to single ‘biomarkers’, the application of this holistic NMR approach and the integrated computational methods provides a data-driven systems biology approach to biomedical research.